The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

Cell Death and Differentiation

Volumn 22, Issue 10, 2015, Pages 1618-1629

  Blazquez C ^a,b   Chiarlone, A ^a,b   Bellocchio, L ^a,b   Resel, E ^a,b   Pruunsild, P ^c   Garcia Rincon D ^a,b   Sendtner, M ^d   Timmusk, T ^c   Lutz, B ^e   Galve Roperh, I ^a,b   Guzman M ^a,b  

^a INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 1 RECEPTOR; DESIGNER DRUG; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DORSOLATERAL STRIATUM; EXCITOTOXICITY; GENE EXPRESSION; GENETICS; IN VIVO STUDY; MALE; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; STRIATE CORTEX; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; HUNTINGTON CHOREA; METABOLISM; PHYSIOLOGY; TRANSGENE;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MICE; MULTIPROTEIN COMPLEXES; NEUROPROTECTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSGENES;

EID: 84941177275     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.11     Document Type: Article

References (70)

1. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923-930.
2. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-1647.
3. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-884.
4. Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011; 163: 1365-1378.
5. Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 2011; 17: 637-644.
6. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011; 163: 1402-1410.
7. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008; 14: 2279-2288.
8. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-88.
9. 1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA 2014; 111: 8257-8262.
10. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14: 7-23.
11. D'Souza DC, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl) 2009; 202: 569-578.
12. Kreitzer AC. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 2009; 32: 127-147.
13. Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999; 19: 5409-5419.
14. Rauskolb S, Zagrebelsky M, Dreznjak A, Deogracias R, Matsumoto T, Wiese S et al. Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. J Neurosci 2010; 30: 1739-1749.
15. Li Y, Yui D, Luikart BW, McKay RM, Rubenstein JL, Parada LF. Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. Proc Natl Acad Sci USA 2012; 109: 15491-15496.
16. Pazos MR, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008; 14: 2317-2325.
17. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-322.
18. Gines S, Bosch M, Marco S, Gavalda N, Diaz-Hernandez M, Lucas JJ et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 2006; 23: 649-658.
19. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011; 134: 119-136.
20. Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010; 30: 14708-14718.
21. Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 2013; 22: 2462-2670.
22. Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J Neurosci 2013; 33: 18712-18727.
23. 2. Pharmacol Rev 2010; 62: 588-631.
24. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000; 9: 2799-2809.
25. Gines S, Ivanova E, Seong IS, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem 2003; 278: 50514-50522.
26. Xifro X, Garcia-Martinez JM, Del Toro D, Alberch J, Perez-Navarro E. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J Neurochem 2008; 105: 1596-1612.
27. Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De Mario A et al. Pitfalls in the detection of cholesterol in Huntington's disease models. PLoS Curr 2012; 4: e505886e9a1968.
28. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007; 90: 397-406.
29. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res 2007; 85: 525-535.
30. Pruunsild P, Sepp M, Orav E, Koppel I, Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J Neurosci 2011; 31: 3295-3308.
31. Zheng F, Zhou X, Luo Y, Xiao H, Wayman G, Wang H. Regulation of brain-derived neurotrophic factor exon IV transcription through calcium responsive elements in cortical neurons. PLoS One 2011; 6: e28441.
32. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 2007; 104: 5163-5168.
33. Lee HM, Giguere PM, Roth BL. DREADDs: novel tools for drug discovery and development. Drug Discov Today 2014; 19: 469-473.
34. Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 2009; 63: 27-39.
35. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
36. Denovan-Wright EM, Robertson HA. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 2000; 98: 705-713.
37. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 2004; 271: 4909-4920.
38. Casteels C, Vandeputte C, Rangarajan JR, Dresselaers T, Riess O, Bormans G et al. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. Exp Neurol 2011; 229: 440-449.
39. Richfield EK, Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 1994; 36: 577-584.
40. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97: 505-519.
41. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 2011; 42: 524-529.
42. Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1997; 282: 1632-1642.
43. Steindel F, Lerner R, Haring M, Ruehle S, Marsicano G, Lutz B et al. Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem 2013; 124: 795-807.
44. Selley DE, Rorrer WK, Breivogel CS, Zimmer AM, Zimmer A, Martin BR et al. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. J Neurochem 2001; 77: 1048-1057.
45. Greer PL, Greenberg ME. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008; 59: 846-860.
46. Hong EJ, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron 2008; 60: 610-624.
47. Tao X, West AE, Chen WG, Corfas G, Greenberg ME. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron 2002; 33: 383-395.
48. Bloodgood BL, Sharma N, Browne HA, Trepman AZ, Greenberg ME. The activity-dependent transcription factor NPAS4 regulates domain-specific inhibition. Nature 2013; 503: 121-125.
49. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 2003; 23:2371-2382.
50. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004; 19: 1691-1698.
51. Rubino T, Vigano D, Premoli F, Castiglioni C, Bianchessi S, Zippel R et al. Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol Neurobiol 2006; 33: 199-213.
52. 1 knockout mice. J Neurochem 2008; 105: 565-572.
53. Beyer CE, Dwyer JM, Piesla MJ, Platt BJ, Shen R, Rahman Z et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol Dis 2010; 39: 148-155.
54. Ferreira-Vieira TH, Bastos CP, Pereira GS, Moreira FA, Massensini AR. A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. Hippocampus 2014; 24:79-88.
55. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-9-tetrahydrocannabinol. J Neurochem 2005; 93: 802-811.
56. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389:856-860.
57. Timmusk T, Lendahl U, Funakoshi H, Arenas E, Persson H, Metsis M. Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. J Cell Biol 1995; 128: 185-199.
58. Canals JM, Marco S, Checa N, Michels A, Perez-Navarro E, Arenas E et al. Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease. Neurobiol Dis 1998; 5: 357-364.
59. Her LS, Goldstein LS. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 2008; 28: 13662-13672.
60. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 2009; 106: 21377-21382.
61. 1 receptor function in the striatum. J Neurosci 2010; 30: 8127-8137.
62. The Huntington's Disease Collaborative Research Consortium A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
63. 2receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003; 23: 11136-11141.
64. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913.
65. 1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2014; 40: 701-712.
66. Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I et al. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron 2014; 83: 178-188.
67. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006; 51: 455-466.
68. 1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One 2010; 5: e15707.
69. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007; 27: 2396-2402.
70. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534.